NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $6.30 +0.28 (+4.65%) (As of 10/11/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Altimmune Stock (NASDAQ:ALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$5.94▼$6.3550-Day Range$5.50▼$7.8852-Week Range$2.09▼$14.84Volume1.87 million shsAverage Volume3.94 million shsMarket Capitalization$447.74 millionP/E RatioN/ADividend YieldN/APrice Target$18.80Consensus RatingModerate Buy Company OverviewAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More… Looking to target extra income OVER the weekend? (Ad)Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…Let me show you how I target extra income as early as THIS weekend! Altimmune Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 38% of companies evaluated by MarketBeat, and ranked 792nd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($0.54) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.52% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Altimmune has recently increased by 2.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted31.52% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Altimmune has recently increased by 2.42%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.71 News SentimentAltimmune has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Altimmune this week, compared to 8 articles on an average week.Search InterestOnly 14 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $110,476.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. ALT Stock News HeadlinesNovo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The NamesOctober 11 at 3:47 PM | benzinga.comAltimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesOctober 9 at 10:39 PM | finance.yahoo.comMSFT, NFLX, GOOGL all winners. MRVL next?Today’s offer is a little different… You’ll see why contrary to what the talking heads in the news want you to believe… Investing in the stock market isn’t as complex as you likely think it is. But first, take a walk with me back to February 2023… Thanks to my special cash flow strategy, I’ve managed to nail winners in 36 of 42 trades…October 12, 2024 | WealthPress (Ad)Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)October 9 at 10:23 AM | markets.businessinsider.comConsider Buying Potential Takeover Target AltimmuneOctober 3, 2024 | seekingalpha.comBrokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $18.80October 2, 2024 | americanbankingnews.comAltimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual ConferenceOctober 1, 2024 | globenewswire.comBiomea Fusion: Recent Rally May Not Last, Despite Upcoming Data CatalystsSeptember 30, 2024 | seekingalpha.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $11.25 on January 1st, 2024. Since then, ALT stock has decreased by 44.0% and is now trading at $6.30. View the best growth stocks for 2024 here. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) announced its earnings results on Thursday, August, 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 24,778.97% and a negative trailing twelve-month return on equity of 53.09%. When did Altimmune's stock split? Altimmune's stock reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Altimmune's top institutional shareholders include Exchange Traded Concepts LLC (0.31%), SG Americas Securities LLC (0.05%) and Creative Planning (0.03%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Wayne Pisano, M Scot Roberts and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings8/08/2024Today10/11/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$18.80 High Stock Price Target$25.00 Low Stock Price Target$12.00 Potential Upside/Downside+198.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-24,778.97% Pretax Margin-24,778.97% Return on Equity-53.09% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio11.30 Quick Ratio11.30 Sales & Book Value Annual Sales$430,000.00 Price / Sales1,041.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.29Miscellaneous Outstanding Shares71,070,000Free Float68,157,000Market Cap$447.74 million OptionableOptionable Beta0.08 This page (NASDAQ:ALT) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredThe Crypto Whisperer Just Sounded the AlarmThe 2024 Altcoin Eruption is Almost Here (Get in by Nov. 4) In late 2020, Ian King urged his readers to tak...Banyan Hill Publishing | SponsoredDon’t Miss Out: Elon’s Game-Changing InventionWhen you click here you'll discover what Elon Musk's newest invention can do… And how it works… You migh...InvestorPlace | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Altimmune, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.